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Abstract
Background: In addition to their central effects, opioids cause peripheral analgesia. There is evidence showing that
peripheral activation of kappa opioid receptors (KORs) inhibits inflammatory pain. Moreover, peripheral μ-opioid
receptor (MOR) activation are able to direct block PGE2-induced ongoing hyperalgesia However, this effect was not
tested for KOR selective activation. In the present study, the effect of the peripheral activation of KORs on PGE2-
induced ongoing hyperalgesia was investigated. The mechanisms involved were also evaluated.
Results: Local (paw) administration of U50488 (a selective KOR agonist) directly blocked, PGE2-induced mechanical
hyperalgesia in both rats and mice. This effect was reversed by treating animals with L-NMMA or N-propyl-L-
arginine (a selective inhibitor of neuronal nitric oxide synthase, nNOS), suggesting involvement of the nNOS/NO
pathway. U50488 peripheral effect was also dependent on stimulation of PI3Kg/AKT because inhibitors of these
kinases also reduced peripheral antinociception induced by U50488. Furthermore, U50488 lost its peripheral
analgesic effect in PI3Kg null mice. Observations made in vivo were confirmed after incubation of dorsal root
ganglion cultured neurons with U50488 produced an increase in the activation of AKT as evaluated by western
blot analyses of its phosphorylated form. Finally, immunofluorescence of DRG neurons revealed that KOR-
expressing neurons also express PI3Kg (≅ 43%).
Conclusions: The present study indicates that activation of peripheral KORs directly blocks inflammatory
hyperalgesia through stimulation of the nNOS/NO signaling pathway which is probably stimulated by PI3Kg/AKT
signaling. This study extends a previously study of our group suggesting that PI3Kg/AKT/nNOS/NO is an important
analgesic pathway in primary nociceptive neurons.
Background
Inflammatory pain is primarily due to the sensitization
of specific classes of nociceptive neurons by the direct
action of inflammatory mediators (e.g., prostaglandins).
In this context, pharmacologic control of inflammatory
pain in the periphery is mainly based on two principal
strategies. First, the use of non-steroidal anti-inflamma-
tory drugs (aspirin and aspirin-like drugs) inhibits
cyclooxygenase-derived prostaglandin production and,
consequently, reduces nociceptor sensitization [1]. This
effect ultimately prevents the development of hyperalge-
sia (decrease in nociceptive threshold) in humans and
animals. On the other hand, the second strategy is
exemplified by some analgesic drugs, like opioids and
dipyrone, which are able to directly block ongoing noci-
ceptor sensitization through peripheral actions [2,3]. In
fact, local (intraplantar, i.pl.) administration of opioids
reversed already established hyperalgesia induced by
prostaglandin E2 (PGE2) [2,4]. Therefore, in contrast to
aspirin-like drugs that act through the prevention of
nociceptor sensitization by inhibiting prostaglandin
synthesis, opioids are able to directly block ongoing
inflammatory hyperalgesia.
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that the inhibition of neuronal nitric oxide synthase
inhibits peripheral antinociception achieved with
opioids, suggesting the participation of nitric oxide [4,5].
These pharmacological data are further supported by
the observation that the peripheral analgesic effect of
morphine is lost in nitric oxide deficient mice [4].
Further addressing the molecular basis of opioid periph-
eral analgesia, we recently de m o n s t r a t e dt h a tt h ep h o s -
phoinositide 3-kinase gamma (PI3Kg)/AKT signaling
pathway is the first step between the activation of μ-
opioid receptors by morphine and selective agonists and
the stimulation of nitric oxide control of peripheral
analgesia.
There are evidences in the literature showing that
activation of kappa opioid receptors (KORs) also inhibits
inflammatory pain [6,7]. For instance, selective KOR
agonist reduces carrageenin-induced hyperalgesia in rats
[6]. Furthermore, the mechanism operating this effect
seems to be dependent on nitric oxide synthase (NOS)/
nitric oxide (NO) signaling pathway [6]. However, it is
not clear which NOS isoform is involved in this effect
and if PI3Kg/AKT signaling is involved. Therefore, in
the present study we tested if the peripheral activation
of KORs also directly blocks ongoing inflammatory
hyperalgesia induced by PGE2. The molecular mechan-
isms involved in this effect were also investigated.
Methods
Animals
The experiments were performed in male Wistar rats
(180-200 g), C57BL/6 wild type (WT) male mice (20-
25 g) and PI3Kg deficient mice (PI3Kg-/-). All animals
were housed in the animal care facility of the Faculty
of Medicine of Ribeirão Preto-University of Sao Paulo.
T h ea n i m a l sw e r et a k e nt ot h et e s t i n gr o o ma tl e a s t1
h before the experiments and were used only once.
Food and water were available ad libitum. The animal
care and handling procedures were in accordance with
the International Association for the Study of Pain
guidelines [8] for those animals used in pain research,
which were approved by the Committee for Ethics in
Animal Research of the Faculty of Medicine of
Ribeirão Preto-USP.
Nociceptive test
The electronic pressure-meter test
The mechanical nociceptive threshold was tested in
mice and rats as previously reported [9,10]. In a quiet
room, mice or rats were placed in acrylic cages (12 × 10
× 17 cm) with wire grid floors 15-30 min before the
start of testing. The test consisted of evoking a hindpaw
flexion reflex with a hand-held force transducer (electro-
nic aesthesiometer; IITC Life Science, Woodland Hills,
CA) adapted with a 0.5 (mice) or 0.7 mm
2 (rats) poly-
propylene tip. The investigator was trained to apply the
tip perpendicularly to the central area of the hindpaw
with a gradual increase in pressure. The endpoint was
considered removal of the paw followed by clear flinch-
ing movements. After paw withdrawal, the intensity of
the pressure was automatically recorded, and the final
v a l u ef o rt h er e s p o n s ew a so b t a i n e db ya v e r a g i n gt h r e e
measurements. The animals were tested before and after
treatments. The results are expressed as the delta (Δ)
withdrawal threshold (in g), calculated by subtracting
the zero-time mean measurements from the time inter-
val mean measurements. The withdrawal threshold was
9.1 ± 0.2 g (mice; mean ± SEM.; n = 30) and 38.8 ± 0.7
(rats; mean ± SEM.; n = 20) before injection of the
hypernociceptive agents. Quantification of nociception
was performed by a blinded observer. Multiple paw
treatments with saline did not alter the basal reaction
time, which was similar to that observed in non-injected
paws.
Thermal nociceptive test
The latency of paw withdrawal to radiant heat stimuli
was measured using a Plantar Ugo Basile apparatus
(Stoelting, Wood Dale, Il) as previously described [11].
Mice can move freely in this apparatus on an elevated
glass surface with plastic boxes above as the top cover.
Mice are given a one h acclimation period prior to test-
ing until they become calm and motionless. A calibrated
infrared light source of high intensity was applied per-
pendicular on the plantar surface of each mouse’sh i n d
paw. The end point was characterized by the removal of
the paw followed by clear flinching movements. Latency
to paw withdrawal was automatically recorded. Each
hind paw was tested alternately with an interval of 5
min for four trials. Paw withdrawal latency of four trials
from both hind paws of each mouse was averaged and
recorded as mean ± SEM.
Primary DRG neuron culture
Rats weighing 100 g were euthanized by decapitation
under isoflurane anesthesia. Dorsal root ganglia were
collected (18-20 ganglia per animal) and transferred to a
sterile Hank’s balanced salt solution (Sigma, St Louis,
MO, EUA) containing HEPES 10 mM (HBSS/HEPES).
Isolated ganglia were incubated with collagenase III
(0.28 U/mL) for 75 min and trypsin (0.25% w/v) for 12
m i ni nH B S S / H E P E S .G a n g l i aw e r ew a s h e da n dr e s u s -
pended in Dulbecco’s Modified Eagle medium (DMEM,
Sigma, USA) containing 10% fetal bovine serum and
penicillin/streptomycin 1000 U/mL. Cells were disso-
ciated by triturating the ganglia with a fire polished pip-
ette and then were plated in six well plastic plates
coated with Matrigel (BD, USA). Cell cultures were
maintained at 37°C and 5% CO2, and experiments were
performed within 24 h [12].
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After the indicated stimulation, DRG cells were homo-
genized in a lysis buffer containing a mixture of protease
inhibitors and phosphatase inhibitors (Sigma). The pro-
tein concentrations of the lysate were determined using
a BCA Protein Assay kit (Pierce, Rockford, IL), and 30
μg of protein was loaded for each lane. Protein samples
were separated on a SDS-PAGE gel (10% gradient gel;
Bio-Rad, Hercules, CA) and transferred to nitrocellulose
membranes (Amersham Pharmacia Biotech, Little Chal-
font, UK). The filters were blocked with 5% dry milk
and incubated overnight at 4°C with a primary antibody,
phosphorylated (p-Ser473) AKT (1:500; Cell Signaling
Technology, Beverly, MA), for 1 h at room temperature
(RT) with an HRP-conjugated secondary antibody
(1:20000; Jackson ImmunoResearch, PA, USA). The
blots were visualized in an ECL solution (Amersham
Pharmacia Biotech) for 2 min and exposed to film
(Hyperfilm, Amersham Pharmacia Biotech) for 1-30
min. A nonphosphorylated AKT (1:1000; Cell Signaling
Technology, Beverly, MA) antibody was used as a load-
ing control [13].
DRG immunohistochemistry
Animals were terminally anesthetized with urethane and
perfused through the ascending aorta with saline, fol-
lowed by 4% paraformaldehyde in a 0.1 M phosphate
buffer, pH 7.4 (4°C). After the perfusion, DRGs were
removed and postfixed in the same fixative for 2 h
before being replaced overnight with 20% sucrose. All of
the DRGs were embedded in OCT, and DRG sections
(14 μm) were cut in a cryostat and processed for immu-
nofluorescence. All of the sections were blocked with
2% BSA in 0.3% Triton X-100 for 1 h at room tempera-
ture and incubated for 2 h at 4°C with a mixture of
polyclonal rabbit anti-PI3Kg (1:200; Santa Cruz, CA,
USA), polyclonal goat anti-Kappa opioid receptors
(1:200; Santa Cruz), antibodies, and, finally, a mixture of
AlexaFluo-488 and AlexaFluo-594 conjugated secondary
antibodies (Molecular Probes, Carlsbad, CA, USA) for 1
h at room temperature.
Drugs
The following drugs were obtained from the sources
indicated. Wortmannin, L-NMMA, naloxone chlorhy-
drate, LY294002, Complete Freund’sA d j u v a n t( C F A ) ,
Nor-Binaltorphimine (Nor-BNI) and PGE2 were pur-
chased from Sigma Chemical Co. (St. Louis, MO, USA).
AS605240 and AKT inhibitor IV were obtained from
Calbiochem (San Diego, CA, USA). N
ω-Propyl-L-argi-
nine was obtained from Tocris Bioscience (Ellisville,
MO, USA).
Data analyses and statistics
All results are presented as the means ± S.E.M. The
experiments were repeated at least twice. A two-way
analysis of variance (ANOVA) was used to compare the
groups and doses at all times curves when the hyperno-
ciceptive responses were measured at different times
after the stimulus injection. The factors analyzed were
treatments, time and time by treatment interaction.
When there was a significant time by treatment interac-
tion, a one-way ANOVA followed by a Bonferroni’s t-
test was performed at each time. Alternatively, when the
hypernociceptive responses were measured once after
the stimulus injection, the differences between responses
w e r ee v a l u a t e db yao n e - w a yA N O V Af o l l o w e db ya
Bonferroni’s t-test. P < 0.05 was considered as
significant.
Results
Activation of peripheral KORs inhibits hyperalgesia
induced by PGE2 in rats and mice
In the first part of this study, we tested the effect of
U50488 (a selective agonist of KORs) on the established
inflammatory hyperalgesia produced by PGE2 in rats
and mice. We previously demonstrated that opioids
post-treatment (2 h after the PGE2 paw injection in rats
and 30 min after the injection in mice) are effective in
reducing mechanical hyperalgesia produced by PGE2 [4].
The local administration of U50488 inhibited PGE2-
induced mechanical hyperalgesia in a dose-dependent
manner in rats (Figure 1A) and in mice (Figure 1C) (3-
30 μg/paw and 1-9 μg/paw, respectively).The dose of
U50488 that produced antinociception after PGE2-
induced hyperalgesia when injected in the ipsilateral
paw of rats was ineffective when injected in the contral-
ateral paw, suggesting a peripheral site of action (Figure
1A). The peripheral antinociceptive effect of U50488
was reversed by local administration of a selective
antagonist of KOR, Nor-BNI (Figure 1B). This local
effect was also observed in mice at doses of 3 and 9 μg
of U50488; however, the dose of 9 μg was able to pro-
duce systemic effects (Figure 1D).
nNOS/NO pathway mediates Antinociception produced
by the peripheral activation of KORs
The participation of NOS/NO in the peripheral antino-
ciception produced by KOR activation was analyzed.
The treatment of mice with L-NMMA (10 mg/kg, s.c,
30 min before U50488) inhibited the peripheral antino-
ciceptive effect of U50488 (Figure 2A). Moreover, the
intraplantar (ipl.) treatment of rats with n-propyl-L-argi-
nine (30 μg/paw) also inhibited the peripheral antinoci-
ceptive effect of U50488 (Figure 2B).
Requirement of PI3Kg for the peripheral antinociceptive
effect of KOR agonist
To investigate if the PI3Kg/AKT mediates the directly
blockage of ongoing hyperalgesia by peripheral activa-
tion of KORs, we initially tested two non-selective
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peripheral antinociceptive effect of U50488. The ipl.
treatment of rats with wortmannin (3 μg/paw) or
LY294002 (10 μg/paw) 30 min before the U50488 (10
μg/paw) injection inhibited the U50488 peripheral anti-
nociceptive effect (Figure 3A and 3B). Next, the effects
of a selective inhibitor of PI3Kg were tested. The treat-
ment of rats with a selective inhibitor of PI3Kg
(AS605240, 30 μg/paw, 30 min before U50488 adminis-
tration) also inhibited the antinociceptive effect of
U50488 (Figure 4A). Doses of PI3Ks inhibitors were
based on dose-response curves performed in a previous
study [4].
The involvement of PI3Kg in the antinociception pro-
duced by peripheral activation of KORs was further
analyzed in PI3Kg deficient mice. In agreement with the
data obtained with PI3K inhibitors, U50488 did not
show peripheral antinociceptive effects in PI3Kg null
mice after PGE2-induced mechanical and thermal hyper-
algesia (Figure 4B and 4C). The PI3Kg dependent
Figure 1 KOR agonist (U50488) directly blocked PGE2-induced
inflammatory hyperalgesia in rats and mice.( A) Mechanical
hyperalgesia in rats was induced by an ipl. injection of PGE2 (100
ng/paw). After 2 h, U50488 (3-30 μg/paw) was administrated into
the ipsilateral or contralateral (CL) paws. Mechanical hyperalgesia
was evaluated 1 h after U50488 injection using the electronic von
Frey test. (B) The antinociceptive effect of a local injection of
U50488 (10 μg/paw, 2 h after PGE2 injection) upon PGE2-induced
hyperalgesia was prevented by treatment with a selective
antagonist of KOR (Nor-BNI; 30 min before U50488 injection) (C-D)
Mechanical hyperalgesia was induced by an ipl. injection of PGE2
(30 ng/paw) in mice. After 30 min, U50488 (1-9 μg/paw) was
administrated into the ipsilateral or contralateral (CL) paws. Data are
expressed as the mean ± S.E.M. of 5-6 animals per group. *
Indicates statistical significance compared to the saline group. #
Indicates statistical significance compared to the PGE2 control
group. P < 0.05, one-way ANOVA, followed by the Bonferroni
correction.
Figure 2 The nNOS/nitric oxide pathway participates in the
peripheral antinociceptive effect of a KOR agonist.( A)
Mechanical hyperalgesia in mice was induced by an ipl. injection of
PGE2 (30 ng/paw). The antinociceptive effect of a local injection of
U50488 (3 μg/paw, 30 min after PGE2 injection) after PGE2-induced
hyperalgesia was prevented by treatment with a non-selective
inhibitor of NOS (L-NMMA, 10 mg/kg, s.c., 30 min before the
U50488 injection) (B) Mechanical hyperalgesia in rats was induced
by an ipl. injection of PGE2 (100 ng/paw). The antinociceptive effect
of U50488 treatment at a locally effective dose (10 μg/paw, 2 h
after PGE2 injection) after PGE2-induced hyperalgesia was prevented
by treatment with a selective inhibitor of nNOS (N-propyl-L-arginine,
30 μg/paw, 30 min before U50488 injection). Data are expressed as
the mean ± S.E.M. of 5-6 animals per group. * Indicates statistical
significance compared to the vehicle group. # Indicates statistical
significance compared to the U50488 treated group. P < 0.05, one-
way ANOVA, followed by the Bonferroni correction.
Figure 3 PI3Ks mediates the peripheral antinociceptive action
of KOR agonists.( A-B) Mechanical hyperalgesia in rats was
induced by an ipl. injection of PGE2 (100 ng/paw). The
antinociceptive effect of U50488 (10 μg/paw, 2 h after PGE2
injection) after PGE2-induced hyperalgesia was prevented by a
pretreatment (30 min) with non-selective inhibitors of PI3Ks:
wortmannin (3 μg/paw) or LY294002 (10 μg/paw). Data are
expressed as the mean ± S.E.M. of 5-6 animals per group. *
Indicates statistical significance compared to the vehicle group. #
Indicates statistical significance compared to the U50488 treated
group. P < 0.05, one-way ANOVA, followed by the Bonferroni
correction.
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of inflammatory pain since U50488 did not present per-
ipheral antinociceptive effect in PI3Kg null mice sub-
jected to CFA-induced hyperalgesia (Figure 4D).
Further supporting these results, immunofluorescence
analyses of rat DRG neurons reveal that KOR-expressing
neurons also express PI3Kg (≅43%) (Figure 5). These
results indicate that PI3Kg mediates the directly blocked
ongoing hyperalgesia produced by peripheral activation
of KORs.
AKT, a PI3Kg downstream signaling kinase, is involved in
the peripheral antinociceptive effect of KOR agonist
AKT is the most important downstream signaling kinase
involved in the cellular effects of PI3Kg [14]. Therefore,
we investigated whether AKT was involved in the per-
ipheral analgesic effect of KOR activation. Local
pretreatment of rat hind paws with a selective AKT
inhibitor (AKT inhibitor IV; 10 μg/paw, 30 min before
U50488) reversed the peripheral antinociceptive effect of
U50488 (Figure 6A). The AKT inhibitor did not affect
the nociceptive threshold when injected alone in the rat
paw (Figure 6A, last bar). To reinforce this in vivo
observation, we analyzed the effect of U50488 on the
activation of the PI3Kg/AKT signaling pathway in cul-
t u r e so fd o r s a lr o o tg a n g l i o n( D R G s )n e u r o n sd e r i v e d
from rats. The incubation of DRG cultured neurons
with U50488 (100 nM) induced a rapid activation of
AKT (5 min), seen as an increase in its phosphorylated
form (Figure 6B). The effect of U50488 returned to
baseline 10 min after incubation (Figure 6B).
Furthermore, the treatment of neurons with naloxone
(NLX- 1 μM), wortmannin (100 nM) or AS605240 (100
nM) inhibited U50488-induced activation of AKT in
Figure 4 PI3Kg mediates the peripheral antinociceptive action
of KOR agonists.( A) Mechanical hyperalgesia in rats was induced
by an ipl. injection of PGE2 (100 ng/paw). The antinociceptive effect
of U50488 (10 μg/paw, 2 h after PGE2 injection) after PGE2-induced
hyperalgesia was prevented by treatment with a selective inhibitor
of PI3Kg (30 μg/paw, 30 min before the U50488 injection). (B)
Mechanical hyperalgesia was induced by the injection of PGE2 (30
ng/paw). After 30 min, U50488 (3 μg/paw) or saline (25 μl)
(indicated by the arrow) was injected in wild type or PI3Kg-/- mice.
(C) Thermal hyperalgesia was induced in mice by the injection of
PGE2 (300 ng/paw). After 15 min, U50488 (10 μg/paw) was injected
in the ipsilateral paws of wild type (WT) or PI3Kg-/- mice (n = 6).
Thermal hyperalgesia was evaluated 1 h after PGE2 injection. (D)
Mice received an intraplantar injection of CFA (10 μl/paw). After 4 h,
U50488 (3 μg/paw) or saline (Sal) was injected in the wild type or
PI3Kg-/- mice. Data are expressed as the mean ± S.E.M. of 5-6
animals per group. * Indicates statistical significance compared to
the vehicle group. # Indicates statistical significance compared to
the U50488 treated group or wild type group. P < 0.05, one-way
ANOVA, followed by the Bonferroni correction.
Figure 5 PI3Kg is expressed in KOR-immunoreactive neurons.
Confocal images of anti-PI3Kg (red, left column) immunoreactivity in
a population of DRG neurons from rats labeled with antibodies to
KORs (green, middle column). Arrows indicate double-labeled
neurons (yellow, right column). Scale bars: 50 μm.
Figure 6 AKT mediates the peripheral antinociceptive action of
a KOR agonist.( A) Mechanical hyperalgesia in rats was induced by
an ipl. injection of PGE2 (100 ng/paw). The antinociceptive effect of
U50488 (10 μg/paw, 2 h after PGE2 injection) after PGE2-induced
hyperalgesia was prevented by treatment of the rat paw with a
selective inhibitor of AKT (AKT inhibitor IV- 10 μg/paw, 30 min
before U50488 injection). Data are expressed as the mean ± S.E.M.
of 5-6 animals per group. * Indicates statistical significance
compared to the vehicle group. # Indicates statistical significance
compared to the U50488 treated group. P < 0.05, one-way ANOVA,
followed by the Bonferroni correction. * P < 0.05, compared with
vehicle treatment. (B) In vitro stimulation of DRG primary culture
neurons from rats with U50488 (100 nM) increased the
phosphorylation of AKT analyzed by Western blot. (C) Pre-incubation
(10 min) with vehicle, wortmannin (WTT - 100 nM), AS605240 (100
nM) or naloxone (NLX- 1 μM) reduced U50488-induced AKT
phosphorylation.
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opioid receptors and PI3Kg in the effect of U50488 (Fig-
ure 6C). Together, these results suggested that the per-
ipheral antinociceptive effect of KOR agonists depends
on the PI3Kg/AKT that in turn might be responsible for
the stimulation of nNOS/NO signaling pathway.
Discussion
Controlling inflammatory pain by peripherally restricted
opioids has been suggested as a possible approach in the
development of new analgesics with fewer undesirable
side effects. In the present study, we expand on this idea
by showing that peripheral activation of KORs by a
selective agonist directly blocks ongoing inflammatory
hyperalgesia induced by PGE2 in rats and mice, avoiding
central side effects. We also provided pharmacological
and biochemical evidence that peripheral activation of
KORs produced antinociception by a mechanism invol-
ving the PI3Kg/AKT/nNOS/NO signaling pathway in
primary nociceptive neurons.
Several studies have shown a peripheral antinocicep-
tive activity of opioids during inflammatory pain. In fact,
peripheral administration of MOR, KOR, and DOR (μ, 
and δ opioid receptor) selective agonists reduced
mechanical or thermal hyperalgesia in different models
of inflammation [2,15-17]. In this context and regarding
the KOR, selective agonists with limited access to the
central nervous system had been developed. They inhib-
ited inflammatory nociception in the following models:
complete adjuvant of Freund-, carrageenin- and zymo-
san-induced paw hyperalgesia, cancer pain, acetic acid-
induced abdominal constriction in mice and formalin-
induced nociception [18-20]. Interestingly, the analgesic
effect of electroacupuncture seems to be mediated, at
least in part, by peripheral activation of KORs [21].
Moreover, a peripherally restricted KOR agonist has
completed Phase I and II clinical trials. The pharmaceu-
tical company announced positive data with significant
pain relief compared to placebo, and it was also safe and
well-tolerated (unpublished observation). Despite this
evidence, the mechanisms controlling antinociception
produced by peripheral KOR activation are not comple-
tely understood.
Inflammatory hyperalgesia depends mainly on the sen-
sitization (increase in excitability) of primary nociceptive
neurons produced by inflammatory mediators. There-
fore, peripheral KOR activation might act by reducing
neuronal excitability. An important question to consider
is if this effect is dependent on the KORs present on
primary nociceptive neurons. The following evidence
supports the hypothesis that peripheral analgesia pro-
duced by KOR activation depends on a direct effect on
nociceptive neurons: a) KORs are constitutively
expressed in primary nociceptive neurons as shown
previously and in the present study [22]; b) activation
of peripheral KORs directly blocks ongoing hyperalge-
s i ap r o d u c e db yP G E 2. The literature presents a con-
vincing argument that PGE2 promotes hyperalgesia by
causing a direct sensitization of primary nociceptive
neurons. Therefore because U50488 inhibits the action
of PGE2,i ti sl i k e l yt h a ti ta c t sd i r e c t l yo np r i m a r y
nociceptive neurons. Peripheral analgesics that act by
inhibition of cyclooxygenase (e.g., NSAIDs) or inhibi-
tion of cytokine production (e.g., glucocorticoids) are
not able to affect PGE2-induced hyperalgesia [23]. On
t h eo t h e rh a n d ,s o m ed r u g s ,l i k em o r p h i n e ,a d e n o s i n e
analogues and cannabinoids, can inhibit the ongoing
sensitization induced by PGE2 by acting directly on
peripheral nociceptive neurons [2,24,25]; c) the periph-
eral antinociceptive effect of morphine or KOR ago-
nists is completely lost in capsaicin-depleted
nociceptors [26,27]; and d) interestingly, it was recently
shown that antinociception produced by systemic
administrated opioids, at least by DOR agonists, is
reduced in mice with a conditional deletion of the
DOR in primary nociceptive neurons [28].
The mechanisms operating peripheral antinociceptive
action of KOR agonists has been evaluated. In fact, it
was shown that bremazocine, considered a selective
KOR agonist, produced peripheral antinociception that
is reversed by treatment with a non-selective inhibitor
of NOS, suggesting the participation of NO signaling
pathway [6]. Herein, we extended this previously find-
ings showing that nNOS is most likely the NOS iso-
form involved in this effect. This conclusion is
supported by the observation that the peripheral anti-
nociceptive activity of U5088 was prevented by selec-
tive and non-selective inhibitors of nNOS. In this
regard, the evidence is similar to that of morphine and
MOR selective agonists [4]. Indeed, morphine and
DAMGO (a MOR selective agonist) lost their periph-
eral antinociceptive effects in nNOS null mice
[4,29,30]. Accordingly, the peripheral antinociceptive
action of Crotalus durissus terrificus snake venom,
which depends on KORs and DORs, is also mediated
by the nNOS/NO signaling [31].
For almost twenty years the mechanism in which NO
signaling is activated by peripheral opioids was unsolved.
However, we recently demonstrated that the activation
of this pathway is preceded by PI3Kg/AKT signaling [4].
In fact, a morphine-induced increase in NO production
by DRG neurons was blocked by incubating cells with
selective inhibitors of PI3Kg and AKT. Furthermore,
morphine’s peripheral antinociceptive effect was inhib-
ited by PI3Kg/AKT selective inhibitors, and it is not
observed in PI3Kg null mice [4]. Apart from peripheral
effects, antinociception produced by systemically or cen-
trally administered opioids was mediated, at least in
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signaling pathway [32-34]. In the present, study we are
showing that the peripheral antinociceptive effect of
KOR is also dependent on activation of PI3Kg/AKT sig-
naling. Based on our previous study [4], it is likely that
PI3Kg/AKT is the link between the activation of KOR
and the stimulation of nNOS/NO signaling pathway.
Although we did not investigate how AKT may modu-
late nNOS activity in our system, there is evidence that
phosphorylation of nNOS at S1416 by AKT increases its
activity [35-37]. Further studies are necessary to explore
this subject in nociceptive neurons.
Another interesting question is how the NO pathway
triggered by KOR activation contributes to peripheral
analgesia. The peripheral analgesic activity of NO
seems to be dependent on cGMP/protein kinase G
and, as a last resort, from the modulation of the cur-
rents of ATP-sensitive potassium channels (KATP)
[4,38]. For instance, the peripheral antinociceptive
activities of opioids, NO donors and cGMP are inhib-
ited by KATP blockers [39,40]. Additionally, in vitro
morphine up-regulates KATP currents in capsaicin-
sensitive neurons through the stimulation of the
PI3Kg/AKT/NO pathway [4]. Up-regulation of KATP
in primary nociceptive neurons by opioids or even by
cGMP seems to be associated with an alteration in the
resting membrane potential, leading to hyperpolariza-
tion of these cells [4,41]. Therefore, it is likely that
activation of KORs might cause a hyperpolarization of
nociceptive neurons, decreasing neuronal excitability
and accounting for peripheral antinociception. This
hypothesis is supported by the finding that application
of KOR agonists at the inflammatory site reduced
spontaneous firing in polymodal nociceptors of ultra-
violet-treated skin [42].
Conclusion
In summary, our results show that peripheral activation
of the KOR receptors directly blocks ongoing hyperalge-
sia induced by PGE2 in mice and rats. This effect seems
to be dependent upon the activation of the KOR recep-
tors expressed by primary nociceptive neurons, trigger-
ing the PI3Kg/AKT which is probably responsible for
the stimulation of nNOS signaling pathway. The devel-
opment of peripherally restricted KOR agonists might
represent a novel strategy for the treatment of inflam-
matory pain.
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